BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, February 12, 2026
Home » Topics » Private » Seed

Seed
Seed RSS Feed RSS

Biospectal Optibp smartphone app

Biospectal raises $4.3M to ramp development of its smartphone-based blood pressure monitoring platform

Aug. 9, 2021
By Bernard Banga
PARIS – Biospectal SA has just closed a $4.3 million seed round to scale its Optibp smartphone blood pressure monitoring application and data platform technology worldwide.
Read More

Amaroq Therapeutics launches with NZ$14M seed funding to develop long non-coding RNA therapies

July 13, 2021
By Tamra Sami
PERTH, Australia – Amaroq Therapeutics Ltd., a spinout out of the University of Otago in Dunedin, New Zealand, has launched after securing NZ$14 million (US$9.7 million) in seed funding to develop long non-coding RNAs to treat breast, colorectal and liver cancer.
Read More

Amaroq Theraeutics launches with NZ$14M seed funding to develop long non-coding RNA therapies

July 9, 2021
By Tamra Sami
PERTH, Australia – Amaroq Therapeutics Ltd., a spinout out of the University of Otago in Dunedin, New Zealand, has launched after securing NZ$14 million (US$9.7 million) in seed funding to develop long non-coding RNAs as therapeutic targets and diagnostic markers to treat breast, colorectal and liver cancer.
Read More
Ochre Bio co-founders Jack O’Meara and Quin Wills

Ochre Bio closes $10M seed round to map and drug the liver

June 16, 2021
By Cormac Sheridan
DUBLIN – Ochre Bio Ltd. has raised $9.6 million in seed financing to drug the liver like never before, by combining genetics, single-cell genomics, spatial sequencing, imaging and machine learning to build a high-resolution, in silico model of the organ, which can provide new insights into disease biology and open up new drug targets.
Read More
Brain and DNA

Vectory taking gene therapy approach to Alzheimer’s with $37.6M seed round

June 15, 2021
By Nuala Moran
LONDON – The pioneers of gene therapy in Europe now aim to take the field to the next level, moving into the development of virally delivered antibodies in the treatment of central nervous system and muscular diseases, with Alzheimer’s disease one of the first targets.
Read More
Cancer cell destruction by nanoparticles

Nanology aims to tackle hypoxic cancer tumors with nano-scale drug delivery tech

June 11, 2021
By David Godkin
TORONTO – Nanology Labs Inc. has raised C$3 million (US$2.49 million) in seed funding to advance development of a polymer-lipid platform that transports nanoparticles into human cells where they “reprogram” hypoxic or oxygen-deprived cancer tumors.
Read More
Emeric Lemaire, Corneliu Malciu and Theo Ryffel

Arkhn raises $5M to lead health care institutions towards sovereignty over efficient data management

June 8, 2021
By Bernard Banga
PARIS – Arkhn SAS has finalized a $5 million seed round to help drive health care institutions towards secure and efficient data management. This financing round has been led jointly by the two French venture capital firms, Kurma Partners SA and Newfund SA, though their respective funds Kurma Diagnostics II and Newfund II.
Read More
RNA
Newco news

Investors Sineup for seed round to advance Transine’s RNA therapeutics

June 2, 2021
By Nuala Moran
LONDON – In a sizeable seed round for a U.K. biotech, Transine Therapeutics Ltd. has raised £9.1 million (US$12.9 million) to take forward a novel method for up-regulating endogenous protein production using a naturally occurring class of long noncoding RNAs.
Read More
Woman wearing K1 Embrace runs up set of stairs

Stoko raises C$6M seed round to market K1 knee brace

May 20, 2021
By David Godkin
TORONTO – Startup company Stoko Inc. has raised C$6 million (US$4.74 million) in seed funding to accelerate market expansion of a device it said will give rigid knee braces a run for their money.
Read More
Audioptics Ossiview Middle Ear Imaging system

Audioptics closes C$1.9M seed round for device that diagnoses middle ear pathologies

May 6, 2021
By David Godkin
TORONTO – Audioptics Medical Inc. has raised a C$1.9 million (US$1.5 million) seed investment round for development of a device that visualizes and assesses the structures of the middle ear to help patients avoid surgery for conductive hearing loss. Audioptics Medical CEO Dan MacDougall told BioWorld the investment marks a major step in his company’s path towards commercial development of its flagship product, the Ossiview Middle Ear Imaging system.
Read More
Previous 1 2 … 11 12 13 14 15 16 17 18 19 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Feb. 12, 2025.
  • Illustration of SCAN in Parkinson’s vs healthy subcortex

    SCAN is core circuit affected in Parkinson’s disease

    BioWorld Science
    Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
  • Woman and 3D brain

    Astellas’ ASP-2246 shows promise in stroke management

    BioWorld Science
    Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for Feb. 10, 2026
  • 3D illustration of skin layers

    TL1A is overexpressed in hidradenitis suppurativa

    BioWorld Science
    Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing